Redeye Members Network

To access members-only content, you must login or register an account. The Redeye membership is free, but you need to apply via our application form.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

NEXT GENERATION INVESTMENT BANKING

  • Peers

Catalyst Potential

It is important to look beyond the numbers and seek a likely catalysts, which could unlock value, and estimate how long it will take for the catalyst to play out. These events, or Catalyst Potential, reduce risk by narrowing the gap between price and value in a more predictable way. This is particularly important when investing in a low-quality business where time is like a ticking bomb stacked against the company.

Catalyst Potential is a Premium members feature in Redeye Universe.

APPLY FOR MEMBERSHIP

Redeye Rating

Mathias Spinnars

Equity Analyst

mathias.spinnars@redeye.se

+46854501330

Company Quality

  • 7.0
  • 1.0
  • 4.0
  • 0.0
  • 0.0

Leadership

Exclusive for members

VD Monica Wallter tillträdde 2015 i samband med bolagets omstrukturering i ledning och styrelse. Dagens ledning har lång erfarenhet från läkemedelsindustrin och utveckling av kliniska projekt. Ledningen backas upp av en erfaren styrelse. Utvecklingen har dragit ut på tiden men bolaget har rättat sig till ny information på ett bra sätt och driver projekten framåt enligt utsago.

Ownership

Exclusive for members

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Profit outlook

Exclusive for members

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Profitability

Exclusive for members

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Capital Strength

Exclusive for members

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Key Model Assumptions - The Bear Case

Exclusive for members

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Key Model Assumptions - The Bull Case

Exclusive for members

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Key Model Assumptions - The Base Case

Exclusive for members

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Latest price

Exclusive for members

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Fair Value Range

Last Price
Key Model Assumptions - The Bear Case
Key Model Assumptions - The Bull Case
Key Model Assumptions - The Base Case

Catalyst Potential

Impact

Timeframe

Short
Mid
Long

Company description

LIDDS är ett forsknings- och utvecklingsbolag med ett projekt i klinisk fas, Liproca Depot. Den långsiktiga ambitionen är att ta fram ett kontinuerligt produktflöde baserat på bolagets teknologiplattform. LIDDS strategi är att utveckla läkemedel fram till fas III för att därefter licensiera ut projekten till läkemedelsbolag med resurser och kompetens att ta projekten vidare till marknad. Read more...

LIDDS är ett forsknings- och utvecklingsbolag med ett projekt i klinisk fas, Liproca Depot. Den långsiktiga ambitionen är att ta fram ett kontinuerligt produktflöde baserat på bolagets teknologiplattform. LIDDS strategi är att utveckla läkemedel fram till fas III för att därefter licensiera ut projekten till läkemedelsbolag med resurser och kompetens att ta projekten vidare till marknad.

LIDDS grundades av forskare och entreprenörer vid Uppsala universitet, Göteborgs universitet samt av life science inkubatorn PULS. LIDDS har sitt huvudsäte i Uppsala och personalstyrkan utgör totalt 5 medarbetare. LIDDS aktie är upptagen till handel på First North sedan 2014.

Less...

TODAY

Day High
7.05
7.00
0.15
-2.1%
Day Low
7.00
Day Open
7.20
Prev Close
7.15
VWAP
7.0
Volume
2K
Turnover
0.017M
Top Broker
NON
VWAP
7.1
Avg Volume
56K
Avg Turnover
0.398M
Top Brokers
AVA/ENS

52 WEEK SUMMARY

Price Range
Beta
n/a
Market Cap
126.0M
Total Return
-5.3%
Trailing P/E
-12.5
Div Yield
0.0%
Shares Outstanding
17.6M
Next Earnings Date
11 May
Stock Exchange
First North Stockholm

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.

Relative Price Strength
Rel Price Chg 3 Months 12.3%
Rel Price Chg 12 Months -19.9%
Volume Trend
Avg Vol 10 vs 60 Days 11.9%
Price vs...
52-Week High -34.9%
50-Day Moving Average 0.5%
200-Day Moving Average 0.5%

Historic pricing of LIDDS

Last price: 7.00 SEK

Loading data...

Prev Close [[ prevClose|number:2 ]] SEK Change [[ changeValue|number:2 ]] %
High [[ highValue|number:2 ]] SEK Avg Daily Volume [[ avgVolume|number:0 ]] Shares
Low [[ lowValue|number:2 ]] SEK Avg Daily Turnover [[ graphAvgTurnover|number:2 ]] SEK

Management

Monica Wallter, CEO
Bengt Norvik, CFO

Executive Board

Jan Törnell, Chairman of the board
Inga-Lill Forslund
Susanna Urdmark
Maria Forss
Anders Norfjäll

Last updated: 2017-03-23 Source: Redeye

Major Holders

Owner Equity Votes
Lars Wikander 9.7%
9.7%
P.U.L.S. AB 4.9%
4.9%
Recipharm Venture Fund AB 4.1%
4.1%
Henry Dunkers Donationsfond & Stiftelser 3.4%
3.4%
Gunvald Berger 3.2%
3.2%
Hans Lennernäs 2.2%
2.2%
BWG Invest Sarl 1.9%
1.9%
East Bay AB 1.8%
1.8%
T-Bolaget AB 1.6%
1.6%
Swedocean 1.4%
1.4%

Last updated: 2017-03-23 Source: Redeye

Insider transaction summary

Total insider purchases and sales reported

Timeframe Transactions Net Shares
Last 12 Weeks

0 Purchases

+ 0

0 Sales

- 0

Last 24 Weeks

0 Purchases

+ 0

0 Sales

- 0

Most recent insider transactions

Exclusive for members
Report Date Name Position Transaction Shares Chg Est Value (SEK)
2015-12-15 Kvist, Sture ANB Sale + 34 23
2015-12-15 Svensson, Sture ANB Sale + 87 11
2015-12-15 Svensson, Kim ANB Sale + 49 151
2015-12-15 Svensson, Sture ANB Sale + 4 162
2015-12-15 Svensson, Malin ANB Sale + 55 126

Source: Millistream – FI

More
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt (SEKm)
  • Capital employed (SEKm)
  • Capital turnover rate
Previous year Next year
2014
  • -8.2%
  • -8.2%
  • -9.9%
  • 0.0%
  • 0.0%
  • 0.0%
  • -0.57
  • -0.57
  • 0.00
  • -1.44
  • 12.5M
  • 69.9
  • -12.4
  • -12.4
  • 0.0
  • 0.0
  • -10.0
  • -10.0
  • 0.9
  • 97.7%
  • 0.0%
  • -18
  • 78
  • 0.0
2015
  • -8.0%
  • -8.0%
  • -10.0%
  • -196,206.3%
  • -196,206.3%
  • -195,380.5%
  • -0.57
  • -0.57
  • 0.00
  • -1.13
  • 13.7M
  • 80.5
  • -12.3
  • -12.3
  • 23,990.9
  • 20,122.0
  • -10.3
  • -10.3
  • 1.0
  • 97.5%
  • 0.0%
  • -15
  • 84
  • 0.0
2016E
  • -5.9%
  • -5.9%
  • -7.5%
  • -63,168.0%
  • -63,168.0%
  • -63,168.0%
  • -0.36
  • -0.36
  • 0.00
  • -1.18
  • 17.6M
  • 102.6
  • -19.5
  • -19.5
  • 9,190.0
  • 10,262.5
  • -16.2
  • -16.2
  • 0.8
  • 100.0%
  • 0.0%
  • -21
  • 93
  • 0.0
2017E
  • -15.9%
  • -15.9%
  • -18.0%
  • -168,500.0%
  • -167,500.0%
  • -167,500.0%
  • -0.95
  • -0.95
  • 0.00
  • -0.23
  • 17.6M
  • 119.4
  • -7.4
  • -7.4
  • 12,238.7
  • 11,937.5
  • -7.1
  • -7.1
  • 1.3
  • 100.0%
  • 0.0%
  • -4
  • 93
  • 0.0
2018E
  • -14.9%
  • -14.1%
  • -14.5%
  • -136,500.0%
  • -134,500.0%
  • -134,099.3%
  • -0.76
  • -0.76
  • 0.00
  • 0.53
  • 17.6M
  • 132.8
  • -9.2
  • -9.2
  • 12,338.2
  • 13,278.5
  • -9.7
  • -9.9
  • 1.5
  • 89.9%
  • 7.1%
  • 9
  • 93
  • 0.0
2019E
  • 11.3%
  • 10.7%
  • 10.9%
  • 49.8%
  • 51.3%
  • 50.8%
  • 0.57
  • 0.57
  • 0.00
  • -0.01
  • 17.6M
  • 123.2
  • 12.4
  • 12.4
  • 6.3
  • 6.3
  • 12.6
  • 12.2
  • 1.3
  • 100.0%
  • 0.0%
  • -0
  • 93
  • 0.2
Previous year Next year
    (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
Previous year Next year
2014
  • 0
  • -7
  • -7
  • -0
  • 0
  • 0
  • -7
  • 0
  • -0
  • 0
  • -7
  • 0
  • -7
2015
  • 0
  • -8
  • -8
  • 0
  • 0
  • 0
  • -8
  • 0
  • 0
  • 0
  • -8
  • 0
  • -8
2016E
  • 9
  • 7
  • 10
  • 0
  • 10
  • 1
  • 4
  • 8
  • 7
  • 3
  • 5
  • 5
  • 8
Q1
  • 0
  • -0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
Q2
  • 0
  • -0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
Q3
  • 0
  • -0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
Q4E
  • 7
  • 4
  • 0
  • 1
  • 2
  • 4
  • 10
  • 0
  • 5
  • 3
  • 2
  • 5
  • 3
2016E
  • 10
  • 10
  • 2
  • 10
  • 7
  • 8
  • 2
  • 3
  • 0
  • 1
  • 6
  • 3
  • 5
2017E
  • 7
  • 5
  • 5
  • 4
  • 4
  • 4
  • 7
  • 3
  • 0
  • 5
  • 6
  • 2
  • 1
Q1E
  • 4
  • 0
  • 4
  • 7
  • 8
  • 8
  • 9
  • 2
  • 6
  • 8
  • 1
  • 0
  • 6
Q2E
  • 2
  • 1
  • 5
  • 2
  • 9
  • 10
  • 5
  • 7
  • 1
  • 10
  • 5
  • 3
  • 0
Q3E
  • 3
  • 6
  • 1
  • 10
  • 5
  • 9
  • 7
  • 8
  • 7
  • 6
  • 7
  • 0
  • 10
Q4E
  • 8
  • 2
  • 3
  • 5
  • 6
  • 9
  • 2
  • 9
  • 6
  • 0
  • 6
  • 6
  • 6
2017E
  • 10
  • 9
  • 2
  • 6
  • 0
  • 7
  • 7
  • 0
  • 8
  • 6
  • 2
  • 8
  • 7
2018E
  • 9
  • 9
  • 6
  • 0
  • 5
  • 9
  • 2
  • 5
  • 8
  • 7
  • 2
  • 2
  • 0
2019E
  • 7
  • 1
  • 5
  • 4
  • 9
  • 10
  • 6
  • 2
  • 7
  • 10
  • 5
  • 8
  • 6
Previous year Next year
    (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
Previous year Next year
2014
  • 18
  • 1
  • 0
  • 0
  • 19
  • 0
  • 0
  • 0
  • 0
  • 0
  • 80
  • 0
  • 80
  • 0
  • 99
  • 0
  • 2
  • 0
  • 2
  • 0
  • 0
  • 0
  • 2
  • 0
  • 0
  • 96
  • 0
  • 96
  • 99
2015
  • 15
  • 0
  • 0
  • 0
  • 16
  • 0
  • 0
  • 0
  • 0
  • 0
  • 86
  • 0
  • 86
  • 0
  • 102
  • 0
  • 3
  • 0
  • 3
  • 0
  • 0
  • 0
  • 3
  • 0
  • 0
  • 100
  • 0
  • 100
  • 102
2016E
  • 4
  • 3
  • 0
  • 9
  • 7
  • 9
  • 6
  • 3
  • 6
  • 1
  • 2
  • 8
  • 0
  • 6
  • 10
  • 4
  • 9
  • 0
  • 7
  • 3
  • 8
  • 0
  • 6
  • 3
  • 6
  • 1
  • 6
  • 6
  • 1
2017E
  • 6
  • 0
  • 10
  • 2
  • 0
  • 0
  • 1
  • 8
  • 8
  • 2
  • 2
  • 6
  • 10
  • 5
  • 10
  • 2
  • 5
  • 4
  • 1
  • 5
  • 2
  • 2
  • 3
  • 10
  • 2
  • 10
  • 4
  • 4
  • 4
2018E
  • 5
  • 4
  • 2
  • 10
  • 5
  • 4
  • 4
  • 5
  • 10
  • 2
  • 7
  • 2
  • 8
  • 3
  • 5
  • 6
  • 5
  • 7
  • 7
  • 5
  • 6
  • 4
  • 5
  • 6
  • 0
  • 4
  • 1
  • 6
  • 0
2019E
  • 6
  • 6
  • 4
  • 1
  • 6
  • 2
  • 2
  • 5
  • 9
  • 2
  • 8
  • 5
  • 2
  • 10
  • 3
  • 2
  • 6
  • 8
  • 8
  • 9
  • 10
  • 8
  • 0
  • 3
  • 2
  • 9
  • 8
  • 10
  • 9
Previous year Next year
    (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow
Previous year Next year
2014
  • 0
  • -7
  • -0
  • -7
  • 0
  • -7
  • 0
  • -7
  • 5
  • -12
  • -14
2015
  • 0
  • -8
  • 0
  • -8
  • 0
  • -8
  • 0
  • -8
  • 0
  • -6
  • -14
2016E
  • 3
  • 2
  • 4
  • 8
  • 4
  • 4
  • 2
  • 8
  • 8
  • 4
  • 10
2017E
  • 5
  • 5
  • 7
  • 5
  • 0
  • 8
  • 10
  • 8
  • 4
  • 2
  • 9
2018E
  • 3
  • 1
  • 9
  • 5
  • 7
  • 0
  • 4
  • 1
  • 10
  • 2
  • 3
2019E
  • 10
  • 1
  • 9
  • 7
  • 0
  • 9
  • 9
  • 6
  • 6
  • 6
  • 7
Previous year Next year
More